# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Jason Cassorla maintains Surgery Partners (NASDAQ:SGRY) with a Buy and lowers the price target from $42 to...
Surgery Partners (NASDAQ:SGRY) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.0...
Benchmark analyst Bill Sutherland reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $50 price target.
Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $43 price ta...
Barclays analyst Andrew Mok initiates coverage on Surgery Partners (NASDAQ:SGRY) with a Equal-Weight rating and announces Pr...
Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $43 price ta...